10x Genomics, Inc.
MX ˙ BMV ˙ US88025U1097
SecurityMX:TXG / 10x Genomics, Inc.
InstitutionFmr Llc
Latest Disclosed Ownership18,543,561 shares
Ownership 15.60%
Fmr Llc ownership in TXG / 10x Genomics, Inc.

2026-03-06 - Fmr Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 18,543,561 shares of 10x Genomics, Inc. (MX:TXG). This represents 15.6 percent ownership of the company. In their previous filing dated 2026-01-08 , Fmr Llc had reported owning 12,696,254 shares, indicating an increase of 46.06 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-03-06 2026-03-06 13G/A 12,696,254 18,543,561 46.06 15.60 44.44
2026-01-08 2026-01-08 13G/A 9,283,772 12,696,254 36.76 10.80 33.33
2025-11-05 2025-11-05 13G/A 11,529,805 9,283,772 -19.48 8.10 -21.36
2025-08-07 2025-08-07 13G/A 9,839,175 11,529,805 17.18 10.30 17.05
2025-08-06 2025-08-06 13G/A 5,647,992 9,839,175 74.21 8.80 69.23
2025-05-07 2025-05-07 13G/A 17,731,269 5,647,992 -68.15 5.20 -68.00
2025-05-07 2025-05-07 13G/A 17,731,269 14,683,871 -17.19 13.00 -20.01
2024-02-09 2024-02-09 13G/A 13,047,330 17,731,269 35.90 16.25 28.39
2023-07-10 2023-07-10 13G/A 8,893,098 13,047,330 46.71 12.66 44.17
2023-02-09 2023-02-09 13G/A 13,278,807 8,893,098 -33.03 8.78 -35.41
2022-02-09 2022-02-09 13G/A 13,746,514 13,278,807 -3.40 13.59 -3.31
2021-12-10 2021-12-10 13G/A 16,661,816 13,746,514 -17.50 14.06 -26.80
2021-02-08 2021-02-08 13G/A 12,141,192 16,661,816 37.23 19.21 2.66
2020-05-11 2020-05-11 13G/A 12,141,192 18.71
2020-02-07 2020-02-07 13G/A 11,334,372 11,719,589 3.40 39.75 -1.18
2019-10-10 2019-10-10 13G 11,334,372 40.22

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F 10X GENOMICS CL A COM 88025U109 17,740,972 5,823,490 48.87 376,641 93.77 0.0039
2026-02-17 2025-12-31 13F 10X GENOMICS CL A COM 88025U109 11,917,482 3,459,481 40.90 194,374 96.59 0.0099
2025-11-13 2025-09-30 13F 10X GENOMICS CL A COM 88025U109 8,458,001 -538,403 -5.98 98,874 -5.09 0.0051
2025-08-14 2025-06-30 13F 10X GENOMICS CL A COM 88025U109 8,996,404 -896,735 -9.06 104,178 20.62 0.0059
2025-05-12 2025-03-31 13F 10X GENOMICS CL A COM 88025U109 9,893,139 -3,561,295 -26.47 86,367 -55.30 0.0055
2025-02-13 2024-12-31 13F 10X GENOMICS CL A COM 88025U109 13,454,434 86,455 0.65 193,206 -35.99 0.0115
2024-11-13 2024-09-30 13F 10X GENOMICS CL A COM 88025U109 13,367,979 357,470 2.75 301,849 19.28 0.0184
2024-08-13 2024-06-30 13F 10X GENOMICS CL A COM 88025U109 13,010,509 81,260 0.63 253,054 -47.85 0.0162
2024-05-13 2024-03-31 13F 10X GENOMICS CL A COM 88025U109 12,929,249 143,713 1.12 485,235 -32.18 0.0326
2024-02-13 2023-12-31 13F 10X GENOMICS CL A COM 88025U109 12,785,536 118,538 0.94 715,479 36.93 0.0550
2023-11-13 2023-09-30 13F 10X GENOMICS CL A COM 88025U109 12,666,998 4,565,400 56.35 522,514 15.50 0.0452
2023-08-11 2023-06-30 13F 10X GENOMICS CL A COM 88025U109 8,101,598 3,729,304 85.29 452,393 85.46 0.0379
2023-08-11 2023-03-31 13F/A-1 10X GENOMICS CL A COM 88025U109 4,372,294 1,169,928 36.53 243,930 109.03 0.0223
2023-05-11 2023-03-31 13F 10X GENOMICS CL A COM 88025U109 4,372,294 1,169,928 243,930 0.0223
2023-02-13 2022-12-31 13F 10X GENOMICS CL A COM 88025U109 3,202,366 -509,836 -13.73 116,694 10.38 0.0116
2022-11-10 2022-09-30 13F 10X GENOMICS CL A COM 88025U109 3,712,202 -2,483,325 -40.08 105,723 -62.29 0.0110
2022-08-12 2022-06-30 13F 10X GENOMICS CL A COM 88025U109 6,195,527 2,070,318 50.19 280,347 -10.66 0.0279
2022-05-13 2022-03-31 13F 10X GENOMICS CL A COM 88025U109 4,125,209 -3,062,865 -42.61 313,805 -70.69 0.0251
2022-02-14 2021-12-31 13F 10X GENOMICS CL A COM 88025U109 7,188,074 -1,177,765 -14.08 1,070,735 -12.08 0.0791
2022-02-14 2021-09-30 13F/A-1 10X GENOMICS CL A COM 88025U109 8,365,839 467,613 5.92 1,217,898 -21.25 0.0966
2021-11-15 2021-09-30 13F 10X GENOMICS CL A COM 88025U109 8,365,839 467,613 1,217,898 0.0966
2021-08-13 2021-06-30 13F 10X GENOMICS CL A COM 88025U109 7,898,226 -1,843,937 -18.93 1,546,630 -12.29 0.1212
2021-05-14 2021-03-31 13F 10X GENOMICS CL A COM 88025U109 9,742,163 -328,920 -3.27 1,763,332 23.65 0.1506
2021-02-08 2020-12-31 13F 10X GENOMICS CL A COM 88025U109 10,071,083 1,484,389 17.29 1,426,065 33.20 0.1269
2020-11-13 2020-09-30 13F 10X GENOMICS CL A COM 88025U109 8,586,694 1,398,273 19.45 1,070,589 66.76 0.1082
2020-08-24 2020-06-30 13F/A-1 10X GENOMICS CL A COM 88025U109 7,188,421 3,996,052 125.18 641,998 222.70 0.0706
2020-08-13 2020-06-30 13F 10X GENOMICS CL A COM 88025U109 7,188,421 3,996,052 641,998 15,772.0121
2020-05-14 2020-03-31 13F 10X GENOMICS CL A COM 88025U109 3,192,369 57,291 1.83 198,948 -16.78 0.0276
2020-02-07 2019-12-31 13F 10X GENOMICS CL A COM 88025U109 3,135,078 385,217 14.01 239,049 72.48 0.0264
2019-11-13 2019-09-30 13F 10X GENOMICS CL A COM 88025U109 2,749,861 2,749,861 138,594 0.0166
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.